Shattuck Labs Set for Major Presentation
Shattuck Labs, Inc. (STTK), a trailblazer in the biotechnology sector focusing on groundbreaking therapeutic solutions, has announced an exciting opportunity to present at a prestigious healthcare conference. This event allows the company to share its latest advancements in therapies targeting various immune-related diseases, making it a significant moment in their ongoing efforts to improve patient care.
Conference Highlights and Management Presentation
At the gathering, Shattuck's management will deliver a comprehensive corporate update. Dr. Taylor Schreiber, the Chief Executive Officer of Shattuck Labs, will be the key presenter. Attendees can look forward to insights from one-on-one meetings alongside the formal presentation, scheduled for 7:30 a.m. PT. This event unfolds at The Westin St. Francis, an iconic venue in the heart of the San Francisco conference scene.
Webcast Availability for Interested Investors
For those unable to attend in person, a live webcast of the presentation will be accessible through the company’s website. This strategic move underscores Shattuck Labs' commitment to transparency and investor engagement. A recording of the presentation will be archived for up to 30 days, ensuring that interested stakeholders can review the information at their convenience.
Focus on Innovative Therapeutics
Shattuck Labs is making significant strides in developing therapies for autoimmune and inflammatory diseases. With a focus on innovative antibody treatments, including a first-in-class candidate targeting inflammatory bowel disease (IBD), the company is at the forefront of medical advancements. Their flagship program, SL-325, is particularly noteworthy, as it aims to disrupt established pathways through its DR3 antagonist antibody, potentially leading to better treatment outcomes.
About Shattuck Labs, Inc.
Based in both Austin, Texas, and Durham, North Carolina, Shattuck Labs, Inc. (STTK) is recognized for its expertise in protein engineering and its commitment to addressing critical health challenges through innovative biologics. The company's approach combines scientific rigor with a patient-centric philosophy, ensuring that they focus on improving quality of life through effective treatments.
Contact Information for Investors
For inquiries, the Investor Relations team at Shattuck Labs is led by Conor Richardson, who serves as the Vice President of Investor Relations. Interested parties can reach out via email at InvestorRelations@shattucklabs.com for further information about the company and its future endeavors.
Frequently Asked Questions
What is Shattuck Labs' core focus?
Shattuck Labs primarily concentrates on developing innovative therapies for autoimmune and inflammatory diseases.
Who will present at the J.P. Morgan Healthcare Conference?
Dr. Taylor Schreiber, the CEO of Shattuck Labs, will be the featured presenter at the event.
How can investors access the presentation?
Investors can view the presentation live via a webcast available on Shattuck Labs' official website.
Where is the conference taking place?
The conference is being held at The Westin St. Francis in San Francisco.
What is SL-325, and why is it significant?
SL-325 is Shattuck Labs' lead therapeutic candidate, designed to target the TL1A/DR3 pathway, potentially revolutionizing treatment for inflammatory bowel disease.
